ClinicalTrials.gg
RecruitingNCT04547166Updated Oct 17, 2024

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

A Phase 2/3 interventional study of HLX10 and HLX04、 in Metastatic Colorectal Cancer, sponsored by Shanghai Henlius Biotech. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
568
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing serplulimab in Colorectal Neoplasms — 12 open to participants now, 12 under way, 2 of them phase 3. serplulimab · Colorectal Neoplasms.

Planned enrollment
Largest of 13
568 · median 51
Started
2021
the only one that year
Phase 2/3
2 of 13
2 open now
Primary completion
2025-09
later than 2 of 11 live
Registered
1st of 13
by date
Lead sponsor
2 of 13
Shanghai Henlius Biotech

Among the 13 studies testing serplulimab in Colorectal Neoplasms, this one has the largest planned enrollment, is the only one that started in 2021, is one of 2 in phase 2/3, reaches primary completion later than 2 of the 11 other live ones, and was the 1st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

12 of the 13 studies testing serplulimab in Colorectal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

About serplulimab

serplulimab: first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing serplulimab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the clinical efficacy of Serplulimab (HLX10) in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination With Bevacizumab and Chemotherapy (XELOX) in First-line Treatment of Patients With Metastatic Colorectal Cancer (mCRC)

Read the detailed description

Patients with confirmed unresectable metastatic/recurrent colorectal adenocarcinoma who have not received systemic anti-neoplastic therapy for metastatic/recurrent lesions will be included in this study.Approximately 6-12 patients will be enrolled in the Part I (Safety Run-in Period).Approximately 100 patients will be enrolled in the Part II (Phase II study, 50 in the test group and 50 in the control group).Approximately 568 patients will be enrolled in the Part III (Phase III study, 284 in the test group and 284 in the control group).

Part II (Phase II study): Approximately 40 study sites in China will participate.

Part III (Phase III study): A total of approximately 75 study sites in 3 countries(including China, Japan, Indonesia) will participate.

The study consists of a screening period (up to 28 days), a treatment period (3-week cycle, up to 2 years), and a follow-up period (including a safety follow-up period, and a survival follow-up every 12 weeks).

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Histopathologically confirmed unresectable /recurrent colorectal adenocarcinoma
  2. ≥ 12 weeks
  3. Have not received any previous systemic anti-tumor drug treatment for metastatic colorectal adenocarcinoma
  4. For participants who have previously received /adjuvant therapy, the time from the last treatment to recurrence or progression must exceed 12 months.
  5. With at least one as assessed by the IRRC per v1.1, and the measurable lesion should not have been treated locally such as with radiotherapy (a lesion located in an area subjected to previous radiotherapy can also be regarded as a measurable lesion if PD is confirmed)
  6. Agree to provide sufficient previously preserved tumor tissue specimens or agree to undergo to collect tumor tissue for some gene test.
  7. Have an PS score of 0 or 1 within 7 days prior to receiving the first dose of the study drugs
  8. Have Adequate major organ functions.

Key Exclusion Criteria:

  1. Have confirmed MSI-H CRC (gene test)
  2. Subjects with oligometastatic liver disease and presenting the potential for becoming resectable
  3. Presence of central nervous system (CNS) or
  4. Have received radiotherapy within 6 months prior to the initiation of study treatment, except for palliative radiotherapy for bone disorders at least 14 days prior to initiation of study treatment; radiotherapy covering more than 30% of the bone marrow area within 28 days prior to randomization is not allowed.
  5. With a history of or current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, severe pulmonary dysfunction, or any condition that may interfere with the detection and management of suspected drug-related pulmonary toxicity
  6. Have received major surgery within 28 days prior to randomization. A major surgery in this study is defined as a surgery requiring at least 3 weeks of recovery to be able to receive the treatment in this study
  7. Previously received intestinal stent implantation, with the stent remaining in place at the screening period
  8. Uncontrolled hypertension despite clinical treatment (defined as systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg)
  9. With a history of hypertensive crisis or hypertensive encephalopathy
  10. With a history of significant/severe hemorrhage within 1 month prior to randomization, or have received blood transfusion within 2 weeks prior to randomization
  11. Requiring long-term treatment with daily administration of nonsteroidal anti-inflammatory drugs (NSAIDs). Occasional use of NSAIDs to relieve medical symptoms such as headache or pyrexia is allowed
  12. With evidence showing the presence of meteorism that cannot be attributed to puncture or recent surgery
  13. Presence of severe, unhealed or split wounds and active ulcers or untreated fractures
  14. Presence of any of the following medical conditions within 6 months prior to randomization:

    1. Abdominal or tracheoesophageal fistula, gastrointestinal perforation or intra-abdominal abscess, massive ascites as judged by the investigator (defined as patients requiring drainage or treatment within two weeks)
    2. Intestinal obstruction and/or previous clinical signs or symptoms of gastrointestinal obstruction, including incomplete obstruction associated with a preexisting disease or requiring routine parenteral hydration, parenteral nutrition, or tube feeding. 2 months prior to randomization, patients with previous symptoms of incomplete obstruction/obstructive syndrome/signs/symptoms of intestinal obstruction that have improved after treatment may be enrolled in the study as assessed by the investigator
    3. Severe, uncontrollable intra-abdominal inflammation requiring clinical intervention as judged by the investigator
    4. Major vascular disease (e.g., aortic aneurysm requiring surgical repair or associated with recent peripheral artery thrombosis)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
568 participants (estimated)

Study arms

  • Experimental
    Serplulima +Bevacizumab+XELOX

    Serplulimab (HLX10) in Combination With Bevacizumab and chemotherapy (XELOX)

    Drug: HLX10 · Drug: HLX04、

  • Placebo comparator
    placebo + Bevacizumab+XELOX

    placebo in combination with Bevacizumab and chemotherapy (XELOX)

    Drug: HLX04、

Interventions

  • DrugHLX10

    a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.

    Also known as: serplulimab

  • 7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.

    Also known as: Bevacizumab

06

What researchers measure

Primary outcomes

  1. PFS

    Progression-free survival (assessed by independent radiological review committee (IRRC) based on RECIST v1.1)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Secondary outcomes

  1. OS

    Overall survival (OS)

    Time frame: From date of randomization until the date of first date of death from any cause, assessed up to 100 months

  2. PFS

    Progression-free survival (assessed by the investigators based on RECIST v1.1)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  3. ORR

    Objective response rate (assessed by independent radiological review and the investigators based on RECIST v1.1))

    Time frame: through study completion, an average of 1 year

  4. Duration of response

    Duration of response

    Time frame: from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier),assessed up to 2 years

  5. DCR

    Disease control rate

    Time frame: the proportion of patients with the best overall response of CR, PR, or stable disease (SD) persisting for 12 weeks

  6. PFS2

    Progression-free survival in the next line of treatment(assessed by the investigators based on RECIST v1.1)

    Time frame: From date of randomization until the date of the second documented PD as assessed by the investigator or date of death from any cause, whichever came first, assessed up to 100 months

07

Study locations

4 of 5 sites recruiting
  • Center for Cancer Prevention and Treatment of Sun Yat-sen University
    Guangzhou, Guangdong 510075, China
    Recruiting
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
    Recruiting
    • Haijun Zhong · Contact0571-87783777
    • · Contact0571-87783777
  • Linyi Cancer Hospital
    Linyi, China
    Recruiting
    • Qingxu Sun, MD · Contact0539-8121800
    • · Contact0539-8121800
  • Fudan University Affiliated Oncology Hospital
    Shanghai, China
    Recruiting
  • National Cancer Center
    Kashiwa, Japan
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Sep 2025, 54 months after the start.

Of 36 phase 2/3 interventional studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 105. This study's planned 54 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2020
First posted
Sep 14, 2020
StartActual
Mar 10, 2021
Primary completionEst.
Sep 24, 2025
CompletionEst.
Dec 30, 2026
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04547166
Responsible party
Sponsor
First posted
Sep 14, 2020
Start date
Mar 10, 2021
Primary completion
Sep 24, 2025 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 17, 2024

Study contacts

Ruihua Xu
Contact
xurh@sysucc.org.cn
020-87343292
Ruihua Xu
study chair · Center for Cancer Prevention and Treatment of Sun Yat-sen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serplulimab

Start the discussion